tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Evommune Inc

EVMN
22.180USD
-1.350-5.70%
終倀 03/27, 16:00ET15分遅れの株䟡
667.12M時䟡総額
損倱額盎近12ヶ月PER


Evommune Inc

22.180
-1.350-5.70%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 䌁業名

Evommune Incの䌁業情報


䌁業コヌド- -
䌚瀟名- -
䞊堎日- -
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類- -
決算期末- -
本瀟所圚地- -
郜垂- -
蚌刞取匕所- -
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌド- -
䞊堎日- -
最高経営責任者「CEO」- -

Evommune Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Eugene A. Bauer, M.D.
Dr. Eugene A. Bauer, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
284.94K
-0.52%
Ms. Janice Drew
Ms. Janice Drew
Executive Vice President - Operations
Executive Vice President - Operations
33.32K
-15.23%
Mr. Luis Pena
Mr. Luis Pena
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Benjamin F. (Ben) McGraw, III
Dr. Benjamin F. (Ben) McGraw, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kyle B. Carver, CPA
Mr. Kyle B. Carver, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gregory S. Moss, Esq.
Mr. Gregory S. Moss, Esq.
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
--
--
Dr. Jeegar P. Patel, Ph.D.
Dr. Jeegar P. Patel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Francois Beaubien, Ph.D.
Dr. Francois Beaubien, Ph.D.
Director
Director
--
--
Dr. David Eric Cohen, M.D.
Dr. David Eric Cohen, M.D.
Independent Director
Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Eugene A. Bauer, M.D.
Dr. Eugene A. Bauer, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
284.94K
-0.52%
Ms. Janice Drew
Ms. Janice Drew
Executive Vice President - Operations
Executive Vice President - Operations
33.32K
-15.23%
Mr. Luis Pena
Mr. Luis Pena
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Benjamin F. (Ben) McGraw, III
Dr. Benjamin F. (Ben) McGraw, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kyle B. Carver, CPA
Mr. Kyle B. Carver, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gregory S. Moss, Esq.
Mr. Gregory S. Moss, Esq.
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Wed, Feb 25
曎新時刻: Wed, Feb 25
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
EQT Partners AB
14.68%
EQT Life Sciences
13.69%
RA Capital Management, LP
9.70%
Pivotal Bioventure Partners Investment Advisor LLC
5.35%
Andera Partners S.A.S.
5.27%
他の
51.31%
株䞻統蚈
株䞻統蚈
比率
EQT Partners AB
14.68%
EQT Life Sciences
13.69%
RA Capital Management, LP
9.70%
Pivotal Bioventure Partners Investment Advisor LLC
5.35%
Andera Partners S.A.S.
5.27%
他の
51.31%
皮類
株䞻統蚈
比率
Venture Capital
36.77%
Private Equity
19.95%
Investment Advisor/Hedge Fund
13.92%
Investment Advisor
12.27%
Hedge Fund
7.84%
Individual Investor
4.19%
Corporation
3.07%
Research Firm
0.18%
Bank and Trust
0.09%
他の
1.71%

機関投資家保有株


曎新時刻: Wed, Jan 21
曎新時刻: Wed, Jan 21
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q4
4
12.40M
0.00%
--
2025Q4
14
14.63M
46.41%
+14.63M

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
EQT Life Sciences
4.93M
15.64%
+4.93M
--
Nov 07, 2025
RA Capital Management, LP
2.21M
7.01%
+2.21M
--
Nov 06, 2025
Pivotal Bioventure Partners Investment Advisor LLC
3.37M
10.68%
+3.37M
--
Nov 06, 2025
Andera Partners S.A.S.
1.90M
6.02%
+1.90M
--
Nov 07, 2025
B Capital Group Management LP
1.10M
3.5%
+1.10M
--
Nov 06, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™